

# Comment

---

Supplementary information to:

## Reboot contraceptives research – it has been stuck for decades

A Comment published in *Nature* **587**, 543–545 (2020)

<https://doi.org/10.1038/d41586-020-03287-0>

---

Sarah G. Chamberlain, Kirsten M. Vogelsong, Michelle Weinberger, Emily Serazin, Sarah Cairns-Smith & Stephen E. Gerrard

---

## **Supplementary information to:**

### **Reboot contraceptives research — it has been stuck for decades**

**A Comment published in *Nature* 587, 543–545 (2020) <https://doi.org/10.1038/d41586-020-03287-0>**

**Sarah G. Chamberlain, Kirsten M. Vogelsong, Michelle Weinberger, Emily Serazin, Sarah Cairns-Smith & Stephen E. Gerrard**

## **Further reading**

Ali, M. & Cleland, J. Contraceptive discontinuation in six developing countries: a cause-specific analysis. *International family planning perspectives*, 92-97 (1995).

Biospace. Allergan Reports Fourth Quarter and Full-Year 2019 Financial Results, <<https://www.biospace.com/article/releases/allergan-reports-fourth-quarter-and-full-year-2019-financial-results/>> (

Callahan, R. L., Mehta, N. J., Nanda, K. & Kopf, G. S. The new contraceptive revolution: developing innovative products outside of industry. *Biology of Reproduction* (2020).

Das, R. Women's Healthcare Comes Out Of The Shadows: Femtech Shows The Way To Billion-Dollar Opportunities, <<https://www.forbes.com/sites/reenitadas/2018/04/12/womens-healthcare-comes-out-of-the-shadows-femtech-shows-the-way-to-billion-dollar-opportunities/#72ec749c6159>> (2018).

FDA. Essure Benefits and Risks, <<https://www.fda.gov/medical-devices/essure-permanent-birth-control/essure-benefits-and-risks>> (2020).

FiercePharma. Got Lolo? Allergan Hypes Ultralow-Estrogen Birth Control in First Major Brand Push, <<https://www.fiercepharma.com/marketing/got-lolo-allergan-hypes-its-super-low-estrogen-birth-control-first-major-brand-campaign>> (2018).

Frost, J. J. & Darroch, J. E. Factors associated with contraceptive choice and inconsistent method use, United States, 2004. *Perspectives on sexual and reproductive health* 40, 94-104 (2008).

Gipson, J. D., Koenig, M. A. & Hindin, M. J. The effects of unintended pregnancy on infant, child, and parental health: a review of the literature. *Studies in family planning* 39, 18-38 (2008).

Grady, W. R., Billy, J. O. & Klepinger, D. H. Contraceptive method switching in the United States. *Perspectives on Sexual and Reproductive Health*, 135-145 (2002).

Hall, K. S., White, K. O. C., Rickert, V. I., Reame, N. & Westhoff, C. Influence of depressed mood and psychological stress symptoms on perceived oral contraceptive side effects and discontinuation in young minority women. *Contraception* 86, 518-525 (2012).

Kaslow, D. C. Overcoming Barriers for Medical Innovations in Low-Resource Settings. *GLOBAL INNOVATION INDEX 2019: Creating Healthy Lives - the Future of Medical Innovation*. 149–155 (2019).

Kirtane, A. R. et al. A once-a-month oral contraceptive. *Science Translational Medicine* 11 (2019).

Levin, L. A. & Behar-Cohen, F. The Academic–Industrial Complexity: Failure to Launch. *Trends in pharmacological sciences* 38, 1052-1060 (2017).

Li, W. et al. Rapidly separable microneedle patch for the sustained release of a contraceptive. *Nature Biomedical Engineering*, doi:10.1038/s41551-018-0337-4 (2019).

Mallapaty, S. Outsourcing discovery. *Nature* 552 (2017).

Matzuk, M. M. & Lamb, D. J. The biology of infertility: research advances and clinical challenges. *Nature medicine* 14, 1197-1213 (2008).

Nelson, A. L., Westhoff, C. & Schnare, S. M. Real-world patterns of prescription refills for branded hormonal contraceptives: a reflection of contraceptive discontinuation. *Obstetrics & Gynecology* 112, 782-787 (2008).

Polis, C. B., Hussain, R. & Berry, A. There might be blood: a scoping review on women’s responses to contraceptive-induced menstrual bleeding changes. *Reproductive health* 15, 114 (2018).

PR Newswire <https://www.prnewswire.com/news-releases/evofem-biosciences-secures-25-million-strategic-investment-from-adjuvant-capital-301152515.html>

Rabely, P. The Future of Contraception., <<https://theltdown.com/future-of-contraception/>> (2020).

Rosenberg, M. J., Waugh, M. & Long, S. Unintended pregnancies and use, misuse and discontinuation of oral contraceptives. *The Journal of reproductive medicine* 40, 355-360 (1995).

Sedgh, G. & Hussain, R. Reasons for contraceptive nonuse among women having unmet need for contraception in developing countries. *Studies in family planning* 45, 151-169 (2014).

Sedgh, G., Singh, S. & Hussain, R. Intended and unintended pregnancies worldwide in 2012 and recent trends. *Studies in family planning* 45, 301-314 (2014).

Speidel, J. J., Townsend, J., Williams, E., Quam, J. & Thompson, K. M. Commentary on research to improve contraceptive and multipurpose prevention technologies. *Contraception* 101, 148 (2020).

Stevenson, C. L., Santini Jr, J. T. & Langer, R. Reservoir-based drug delivery systems utilizing microtechnology. *Advanced drug delivery reviews* 64, 1590-1602 (2012).

Sullivan, F. Femtech - Time for a Digital Revolution in the Women’s Health Market. (2018).

Today, U. Nuvaring Case Finalized in \$100M Settlement, <<https://www.usatoday.com/story/money/business/2014/06/05/nuvaring-settlement-decided/10030941/>> (2014).

Westhoff, C. L. et al. Oral contraceptive discontinuation: do side effects matter? *American journal of obstetrics and gynecology* 196, 412. e411-412. e417 (2007).

**Acknowledgments:**

Many thanks go to colleagues at Avenir Health and EvaluatePharma for providing supporting data. Also, many thanks to colleagues at The Bill & Melinda Gates Foundation, the Boston Consulting Group, Jim Larson, Sean Jeffries, Sam Gardner, Ann Stars, Nomi-Fuchs Montgomery, Jane Wickstrom, Antonio Spina, Frank DelPizzo, and Rebecca Scholz for input and dialogue into this work.